Loading
institutionsInstitution
Indian Institute of Technology Bombay
The engineering institute whose bioscience department, with Tata Memorial, built India's first home-grown CAR-T cell therapy and spun it out as ImmunoACT.
Also called: IIT BombayIITB
Overview
IIT Bombay, founded in 1958 on a 545-acre campus at Powai, is one of India's leading technical universities. Its Department of Biosciences and Bioengineering hosts the laboratory of Rahul Purwar, where research on a humanised CD19 CAR-T construct began in 2013; the programme partnered with Tata Memorial Centre and ACTREC for clinical development, was spun out as ImmunoACT in 2018, dosed its first patients at Tata Memorial Hospital in 2021 and won India's first CAR-T approval (NexCAR19, talicabtagene autoleucel) in 2023. The institute also works on cancer imaging, medical devices and computational biology.
Location
Mumbai, IN
Type
university
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#203 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Indian Institute of Technology Bombay, including child institutions. 80 works · 607 citations · 35% open access · 16% clinical trials · 0% reviews.
Oncology works per year
162022
172023
182024
152025
142026
Most works
- Rahul Purwar20 works
- Atharva Karulkar18 works
- Juber Pendhari16 works
- Shreshtha Shah14 works
- Afrin Firfiray13 works
- Lingaraj Nayak13 works
- Smrithi Ravikumar13 works
- Nirali N. Shah12 works
- Manju Sengar12 works
- Devanshi Kalra12 works
Most cited
- Biosciences and Bioengineering (CAR-T origin)
- Medical devices and imaging
- Digital health
Similar pages
- PersonHasmukh Jain
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, ImmunoACT, Talicabtagene autoleucel (NexCAR19) phase 1/2, Talicabtagene autoleucel.
- PersonGaurav Narula
Shares Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study, ImmunoACT, Talicabtagene autoleucel (NexCAR19) phase 1/2, Talicabtagene autoleucel.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
- TreatmentVarnimcabtagene autoleucel
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Manufacturing cost and time for living and radioactive medicines, CD19.
- TrialIMAGINE (varnimcabtagene autoleucel, Immuneel)
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
- CompanyCipla
Shares ImmunoACT, Talicabtagene autoleucel, Most of the world has almost no cancer care, CAR-T cell therapy.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care, CAR-T cell therapy.
fronts
technologies
targets
drugs
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19